VSTM (Verastem Oncology) רווח למניה בארבעת הרבעונים האחרונים

Verastem, Inc. (VSTM) is building a targeted therapy network for rare tumors, utilizing unique RAS/MAPK inhibitors to align clinics with its protocols. The rolling period's annual change in net income per share demonstrates the current balance of demand, where the value of 53.80 characterizes this level. Verastem, Inc. (VSTM) is implementing treatment regimens for lung and ovarian cancers, anticipating accelerated FDA approval for combination therapies.

The integration of laboratory automation and software robots into the screening processes of Verastem, Inc. (VSTM) is reflected in the YoY TTM earnings per share dynamics on the GURU.Markets platform. This indicator measures the annual growth rate of net income over the last four quarters with daily updates, allowing investors to assess the sustainability of yield growth and avoid overpaying for the asset at a local peak.